ESPE Abstracts (2022) 95 P1-155

ESPE2022 Poster Category 1 Pituitary, Neuroendocrinology and Puberty (77 abstracts)

Evaluation of the influence of the gonadotropin-releasing hormone agonist therapy on growth and body mass index in girls with idiopathic central precocious puberty

Zeynep Donbaloğlu , Aynur Bedel , Ebru Barsal Çetiner , Berna Singin , Bilge Aydın Behram , Hale Tuhan & Mesut Parlak

Akdeniz University Hospital, Antalya, Turkey

Objective: We aimed to examine the auxological findings of the girls diagnosed with idiopathic central precocious puberty (CPP) at the end of the Gonadotropin-releasing hormone analogs (GnRHa) treatment and to investigate the effect of related factors on the height gain of those patients.

Methods: This study was designed as single-center, descriptive, cross-sectional retrospective study. A total of 43 patients who were diagnosed with idiopathic CPP and treated with GnRHa between 2012 - 2021 were included in to study.

Results: The mean chronological age (CA) of the subjects was 7.39 ± 0.76 years at the treatment initiation and 10.93 ± 0.21 at the end of the therapy. The mean treatment duration was 3.96 ± 1.37 years. A decline in height standard deviation score (SDS) from 1.20 ± 0.14 to 1.02 ± 0.06 during the therapy was observed (P<0.001). The bone age (BA)/CA ratio was decreased and predictive adult height (PAH) was increased at the end of the therapy (P<0.001; P=0.001). Both the rates of overweightness and obesity were increased (38.6% to 50% and 9% to 15.9%) when the treatment onset compared with the end of therapy. At the end of the treatment; the mean body mass index (BMI) SDS of the overweight patients was still higher compared to the normal-weight group and the change in BMI SDS during the treatment in the overweight group (BMI median: 1.39 to 1.81; ΔBMI: 0.42) was higher than the change in the BMI SDS in the subjects with normal weight during the treatment (BMI median: 0.32 to 0.46; ΔBMI: 0.14) (P<0.001). There were no significant correlations between pre-treatment BMI and height parameters (Pre- and after-treatment height SDS as well as pre- and after-treatment PAH SDS). While Δheight and height velocity (HV) at the 1st year were higher at the patients whose treatment was initiated before the age of 7 years; both pre- and after-treatment height and PAH SDS were similar in two groups (P<0.0001; P<0.032; P=0.528; P=0.768; P=0.928; P=0.858).

Conclusion: A decrease in bone maturation rate and an increase in PAH were observed with GnRHa treatment which had a positive effect on height potential. The HV at 1st year and Δheight were higher when the treatment was initiated under the age of 7. An increase in BMI during the therapy has been also demonstrated especially in subjects who were overweight before treatment.

Volume 95

60th Annual ESPE (ESPE 2022)

Rome, Italy
15 Sep 2022 - 17 Sep 2022

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.